On second thought, Oncopeptides decides not to give up on Pepaxto in the U.S., but won’t say why kdunleavy Mon, 01/24/2022 – 11:28 More: On second thought, Oncopeptides decides not to give up on Pepaxto in the U.S., but won't
read morePfizer takes a surprising hit to its rare disease plan as FDA snubs new growth deficiency med aliu Mon, 01/24/2022 – 10:27 More: Pfizer takes a surprising hit to its rare disease plan as FDA snubs new growth deficiency med
read moreWith omicron on the prowl, FDA extends inspection pause into February fkansteiner Mon, 01/24/2022 – 10:01 More: With omicron on the prowl, FDA extends inspection pause into February Source: fierce
read moreAbbVie’s Skyrizi nabs psoriatic arthritis nod, its second, shortly after Rinvoq fkansteiner Mon, 01/24/2022 – 09:03 More: AbbVie's Skyrizi nabs psoriatic arthritis nod, its second, shortly after Rinvoq Source: fierce
read moreBeckley Psytech leads a new project focused on addressing psychiatric and neurological conditions through the use of psychedelic medicines. More: Training begins for psychedelic-assisted clinical trial Source: News
read moreThe phase 3 trial involved over 800 candidates to assess ensifentrine when administered as a maintenance therapy to patients diagnosed with COPD. More: Enrol call: Verona recruits 800 patients for COPD trial Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals